Investor Presentaiton

Our Specialty Initiatives. Ramping up Specialty Pipeline SUN PHARMA • In-licensed MK-3222 (a monoclonal antibody undergoing Phase-III trials targeting IL-23) from MSD for treating chronic plaque psoriasis • Entered into a joint venture with Intrexon Corporation for developing gene-based therapies for ocular diseases • Acquired Dusa Pharma in US – Gets access to patented drug-device combination useful for treating Actinic Keratosis, a dermatology ailment • Acquired InSite Vision - Focuses on developing new specialty ophthalmic products, has three late stage programs. Branded Businesses in US, India and ROW • Ranked no. 3 branded dermatology company in the US market • Market leader in specialty chronic segments in India • Amongst the largest Indian companies in branded emerging markets Complex Generics in US • Firmly established as the no. 1 supplier of generic dermatology products in the US • Current product offering in US includes many specialty generics across different dosage forms. Future product development targeted at complex generics • One of the few companies globally to have farm-to-market capabilities for controlled substances • Key focus areas include dermatology, ophthalmic, oncology, controlled substances, amongst others © Sun Pharmaceutical Industries Limited. All Rights Reserved. 8

View entire presentation